Cefmenoxime
A third-generation parenteral cephalosporin antibiotic with broad-spectrum activity against gram-negative bacteria including Pseudomonas and Enterobacteriaceae. It is used for serious infections including respiratory, urinary, and intra-abdominal infections. Like some other cephalosporins, it contains an N-methylthiotetrazole side chain that may affect alcohol tolerance and vitamin K metabolism.
Masse moléculaire
511,6000 g/mol
LogP
0,00
TPSA
270,00 Ų
Règle des 5 de Lipinski
Non conforme
Mécanisme d'action
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Structure 2D
Cite this structure
Embed this structure
SMILES
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@H]12)c1csc(N)n1
InChI
InChI=1S/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1
Molecular Formula
C16H17N9O5S3
HBD / HBA
3 / 14
Liaisons Rotatives
8
Atomes Lourds
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A third-generation parenteral cephalosporin antibiotic with broad-spectrum activity against gram-negative bacteria including Pseudomonas and Enterobacteriaceae. It is used for serious infections including respiratory, urinary, and intra-abdominal infections. Like some other cephalosporins, it contains an N-methylthiotetrazole side chain that may affect alcohol tolerance and vitamin K metabolism.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefmenoxime is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201224. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9570757. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefmenoxime"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefmenoxime/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefmenoxime/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefmenoxime/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefmenoxime"></drugfyi-drug>